Lundbeck Completes Enrollment in Phase III Dravet Trial
Copenhagen, Denmark, September 15, 2026 H. Lundbeck A/S has announced that the last patient has been randomized in DEEp...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine solid tumors targeted therapy
Copenhagen, Denmark, September 15, 2026 H. Lundbeck A/S has announced that the last patient has been randomized in DEEp...
SAN DIEGO, May 8, 2026 Actio Biosciences announced the initiation of the KYRON Phase 1b/2 clinical trial evaluating ABS-1230,...
